Education
About Us
Working with TipRanks
Follow Us
CellaVision AB (SE:CEVI)
:CEVI
Top Page
CellaVision AB
(CEVI)
Select Model
Select Model
Rating:68Neutral
Price Target:
kr174.00
▲(12.99% Upside)
CellaVision AB's overall stock score is driven by strong financial performance and strategic initiatives, which are offset by bearish technical indicators and valuation concerns. The company's solid profitability and low leverage are significant strengths, while the current market sentiment and valuation metrics suggest caution.
Positive Factors
Strong Financial Health
A strong balance sheet with low leverage provides financial stability and resilience, allowing the company to invest in growth opportunities without significant risk.
Innovation and Product Development
Ongoing innovation and new product development, such as the bone marrow application, position CellaVision for future growth and enhanced market competitiveness.
High Profit Margins
Strong profit margins reflect efficient operations and cost management, supporting sustainable profitability and competitive advantage in the market.
Negative Factors
Regional Performance Issues
Challenges in the APAC region, including inventory and shipping issues, could hinder growth and require strategic adjustments to improve market performance.
Currency Headwinds
Currency fluctuations can negatively impact revenue and profitability, posing a risk to financial performance, especially in international markets.
Competition in China
Intense competition and pricing pressures in China may limit market share growth and require strategic efforts to maintain competitiveness.
CellaVision AB (CEVI) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
$3.67B
Dividend Yield1.62%
Average Volume (3M)36.08K
Price to Earnings (P/E)24.3
Beta (1Y)0.75
Revenue Growth1.53%
EPS Growth0.79%
CountrySE
Employees228
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)1.30
Shares Outstanding23,851,547
10 Day Avg. Volume30,505
30 Day Avg. Volume36,083
Financial Highlights & Ratios
PEG Ratio4.57
Price to Book (P/B)6.36
Price to Sales (P/S)7.17
P/FCF Ratio42.98
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue5.32
Enterprise Value/Gross Profit7.70
Enterprise Value/Ebitda17.33
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CellaVision AB Business Overview & Revenue Model
Company DescriptionCellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.
How the Company Makes MoneyCellaVision generates revenue primarily through the sale of its advanced digital microscopes and software solutions designed for automated blood sample analysis. The company operates on a model that includes direct sales of equipment, as well as recurring revenue from software licenses and maintenance agreements. Key revenue streams include the initial sale of hardware systems, ongoing software subscriptions, and service contracts. Additionally, CellaVision has established partnerships with various distributors and strategic alliances within the healthcare sector, which help expand its market reach and drive sales. These partnerships, along with a focus on providing high-quality, reliable diagnostic solutions, contribute significantly to the company's earnings.
CellaVision AB Earnings Call Summary
Earnings Call Date:Nov 06, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Feb 05, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mixed picture with several strategic advancements and organic growth offset by regional performance issues and currency headwinds. The company's strategic initiatives and innovation efforts show potential for future growth, but current challenges in certain markets and financial metrics present areas of concern.Q3-2025 Updates
Positive Updates
Organic Sales Growth
Despite a net sales decrease of 1.7%, CellaVision achieved an organic sales increase of 2.6% compared to the previous year.
EBITDA Improvement
EBITDA improved from SEK 49 million to SEK 50 million, resulting in an EBITDA margin of 28%.
Progress in Strategic Projects
Completion of clinical trials and submission for CE Marking for the bone marrow application, expected by early 2026.
Reagents Segment Growth
The reagents segment saw a growth of 14%, indicating a positive trajectory in this business area.
Software and Innovation
The software upgrade was finalized and installed at customer sites, with an enhanced user experience and functionality.
Negative Updates
Negative Currency Effects
The company faced a currency headwind of minus 4.3%, impacting overall sales figures.
APAC Soft Quarter
APAC region reported only SEK 13 million in sales, with a 10% growth on a low base, impacted by inventory and shipping issues.
Challenges in China
Fierce competition in China with local players and pricing pressures, despite strategic initiatives to manufacture locally.
Timing and Cash Flow Issues
A significant increase in accounts receivable due to late quarter orders, impacting cash flow negatively by SEK 22 million.
Company Guidance
In the CellaVision Q3 2025 report, CEO Simon Østergaard discussed a softer quarter with mixed regional performance, influenced by currency effects. Net sales decreased by 1.7% to SEK 176 million, though organic sales grew by 2.6% compared to the previous year, despite a 4.3% FX headwind. EBITDA increased slightly to SEK 50 million, equating to a 28% margin. The company emphasized its strategic progress, including the completion of a clinical trial and submission for CE Marking of its bone marrow application, expected early 2026. They also highlighted an upgraded software for their platforms, set to roll out in the current quarter. Gross margin improved to 69%, aided by price increases and product mix adjustments. Operating expenses totaled SEK 82 million, with significant R&D investments accounting for 24% of sales, although capitalization was lower at SEK 14 million. The operating cash flow was SEK 29.6 million, with a total cash flow of SEK 4 million after investments and finance activities. Regionally, the Americas saw SEK 68 million in sales with a 4% organic growth, while EMEA recorded SEK 96 million with 1% growth. APAC reported SEK 13 million, reflecting a 10% growth but on a low base. The company is optimistic about its strategic directions, particularly with its bone marrow application and software upgrades expected to enhance future growth.CellaVision AB Financial Statement Overview
Summary
CellaVision AB demonstrates strong financial health with robust revenue growth and profitability. The balance sheet is stable with low leverage, providing resilience against economic fluctuations. Cash flow generation is healthy, although there is potential to enhance free cash flow conversion.Income Statement
CellaVision AB has demonstrated strong growth with a consistent increase in total revenue over the years, achieving a revenue growth rate of 3.41% in the TTM. The gross profit margin is robust at 68.47% for the TTM, indicating effective cost management. The net profit margin of 20.34% reflects solid profitability. Both EBIT and EBITDA margins are strong, at 26.20% and 31.53% respectively, showcasing operational efficiency.85
Very Positive
Balance Sheet
The balance sheet of CellaVision is solid with a low debt-to-equity ratio of 0.03, indicating minimal leverage. The equity ratio stands at a healthy 80.31%, showcasing financial stability. Return on equity is impressive at 18.14%, reflecting efficient use of shareholder funds. However, the low liability level might suggest underutilized leverage potential.78
Positive
Cash Flow
CellaVision's cash flow position is stable with a positive free cash flow growth rate. The operating cash flow to net income ratio is 1.24, indicating good cash generation relative to earnings. However, the free cash flow to net income ratio at 0.44 suggests room for improvement in converting earnings into free cash flow.72
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 748.45M | 723.22M | 677.29M | 639.34M | 565.55M | 471.44M |
| Gross Profit | 517.25M | 487.07M | 463.04M | 438.32M | 392.30M | 313.04M |
| EBITDA | 229.98M | 219.75M | 207.25M | 198.36M | 193.60M | 134.37M |
| Net Income | 151.41M | 140.72M | 130.31M | 118.33M | 125.34M | 89.48M |
Balance Sheet | ||||||
| Total Assets | 1.08B | 1.01B | 928.71M | 891.75M | 825.21M | 668.02M |
| Cash, Cash Equivalents and Short-Term Investments | 158.67M | 149.43M | 121.64M | 108.05M | 130.29M | 102.26M |
| Total Debt | 27.26M | 26.85M | 64.70M | 102.50M | 136.65M | 132.78M |
| Total Liabilities | 224.75M | 196.16M | 212.32M | 250.12M | 281.93M | 238.41M |
| Stockholders Equity | 851.50M | 815.73M | 716.39M | 641.63M | 543.28M | 429.62M |
Cash Flow | ||||||
| Free Cash Flow | 61.53M | 120.69M | 109.96M | 67.85M | 75.41M | 37.47M |
| Operating Cash Flow | 195.10M | 198.44M | 196.44M | 137.28M | 159.72M | 71.12M |
| Investing Cash Flow | -92.79M | -76.01M | -85.53M | -70.01M | -84.34M | -34.96M |
| Financing Cash Flow | -81.11M | -95.09M | -97.04M | -90.41M | -48.48M | -35.22M |
CellaVision AB Technical Analysis
Negative
154.00
Price Trends
166.52
Negative
170.08
Negative
174.13
Negative
Market Momentum
-3.67
Negative
43.81
Neutral
49.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CEVI, the sentiment is Negative. The current price of 154 is below the 20-day moving average (MA) of 156.66, below the 50-day MA of 166.52, and below the 200-day MA of 174.13, indicating a bearish trend. The MACD of -3.67 indicates Negative momentum. The RSI at 43.81 is Neutral, neither overbought nor oversold. The STOCH value of 49.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CEVI.
CellaVision AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $3.67B | 24.26 | 17.89% | 1.62% | 1.53% | 0.79% | |
66 Neutral | kr1.05B | 45.00 | 6.93% | ― | -5.80% | -65.99% | |
63 Neutral | kr5.92B | 197.96 | 1.32% | ― | 8.39% | -85.36% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr1.30B | -1.91 | -57.26% | ― | -23.24% | 45.32% | |
48 Neutral | kr1.03B | -25.42 | -4.42% | ― | 13.48% | 28.98% | |
43 Neutral | kr841.10M | -6.17 | -36.55% | ― | 62.24% | 21.16% |
* Healthcare Sector Average
SE:CEVI
CellaVision AB
154.00
-64.22
-29.43%
SE:BICO
BICO Group AB Class B
18.48
-14.02
-43.14%
SE:SEZI
Senzime AB
5.35
-0.43
-7.42%
SE:XVIVO
Xvivo Perfusion AB
187.90
-285.10
-60.27%
SE:CRAD.B
C-Rad AB Class B
31.05
1.75
5.97%
SE:SEDANA
Sedana Medical AB
10.40
-9.50
-47.74%
CellaVision AB Corporate Events
CellaVision Reports Mixed Q3 Performance Amid Strategic Advancements
Nov 6, 2025
CellaVision AB’s third quarter of 2025 showed mixed regional performance with a slight decrease in net sales, impacted by currency effects and changes in the supply chain. Despite these challenges, the company remains optimistic about its long-term growth, driven by strong demand for its products, particularly in the US and APAC regions. Strategic advancements include the completion of European clinical trials for a new bone marrow application and the upcoming launch of upgraded software for hematology analyzers, reflecting CellaVision’s commitment to innovation and enhanced diagnostic solutions.
CellaVision to Present Q3 2025 Report on November 6
Oct 23, 2025
CellaVision AB announced the release of its third-quarter 2025 report on November 6, inviting analysts, investors, and media to a conference call and webcast for a presentation by CEO Simon Østergaard. This event underscores the company’s commitment to transparency and engagement with stakeholders, potentially impacting its market positioning and investor relations.
CellaVision Announces Nomination Committee for 2026 AGM
Oct 21, 2025
CellaVision has announced the formation of its Nomination Committee ahead of the 2026 Annual General Meeting, scheduled for April 28 in Lund. The committee, chaired by Joel Eklund, will propose candidates for key positions such as the Chairman of the General Meeting and members of the Board of Directors. This announcement is a routine part of CellaVision’s governance process, ensuring structured leadership and strategic planning for the company’s future operations.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.